Investing in Tomorrow's Health
NCL Technology Ventures invests transformational equity capital in entrepreneurs who have truly innovative technologies.
Our Investment Strategy
We invest in Seed and Series A rounds where we can deploy our expertise and capital to help our companies achieve an early inflection point in valuation. We consciously choose investments that create an impact on the lives of patients as well as financial return for our investors.
Our Value Add:
We provide a package of human and capital resources over the life of our investments including:
- – Strong scientific knowledge and frontline healthcare experience
- – Developmental and leadership building experience
- – A carefully built local and global network of healthcare specialists
- – An overriding ambition to succeed in bringing new innovation in healthcare to benefit global recipients
“We are pleased with the performance of Fund 1 and have therefore decided to back Fund 2 as a cornerstone investor.”
– Health Technology Fund II LP
NCLs Health Technology Fund II
NCL has recently launched it Health Technology Fund II. The fund has been designed to take positions in pioneering new technologies that can create significant patient impact and produce upper quartile investment returns.
The fund has launched in partnership with several leading UK institutions including Kings College, NHS and our delivery partner Catalent Inc (NYSE: CLT). Documentation can be provided to professional investors only upon request.
Whether a potential investor or an entrepreneur we invite you to discuss your goals and ambitions with us.
Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management and is supported by an expert Scientific Advisory Board.
Ampersand Health – NHSX today at #REWIRED22 announced the latest winners from the second cohort of the Digital Health Partnership Award.
Ampersand Health are excited to be working in partnership with St George’s University Hospitals NHS Foundation Trust, Thriva Health and Firefly Scientific Limited to collaboratively implement new patient pathways, … Continued
U.S. Food and Drug Administration (FDA) has granted TC Biopharm (NASDAQ:TCBP) lead product, OmnImmune, orphan drug designation, to treat acute myeloid leukemia (AML). Shares of (TCBP) … Continued
London, UK, 16 February 2022: Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, … Continued
Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform
REẖOVOT, Israel, November 15, 2021 (Newswire.com) – Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform. Curesponse is a cancer precision … Continued